Refine
Document Type
- Article (61)
- Preprint (23)
- Contribution to a Periodical (2)
Has Fulltext
- yes (86)
Is part of the Bibliography
- no (86)
Keywords
- SARS-CoV-2 (29)
- COVID-19 (19)
- Omicron (5)
- PCR (5)
- coronavirus (4)
- antiviral therapy (3)
- vaccination (3)
- Autopsy (2)
- BA.1 (2)
- COVID-19 surveillance (2)
- PRNT (2)
- SARS-CoV-2 monitoring (2)
- SARS‐CoV‐2 (2)
- corona virus (2)
- disease burden (2)
- hepatitis B (2)
- in vitro (2)
- infectivity (2)
- influenza (2)
- neutralizing antibodies (2)
- out-patient paediatrics (2)
- respiratory tract infection (2)
- saliva (2)
- sub-lineage (2)
- vaccine (2)
- 17‐OH itraconazole (1)
- 2-deoxy-d-glucose (1)
- 2019-nCoV (1)
- ACE inhibitor (1)
- ALF (1)
- ARDS (1)
- AT1 receptor antagonist (1)
- Ag-RDT (1)
- Anti-CMV IgG (1)
- Antigen test (1)
- B.1.1.529 (1)
- B.1.1.7 (1)
- B.1.617.1 (1)
- B.1.617.2 (1)
- BA.4 (1)
- BA.5 (1)
- BNT162b2 (1)
- BNT2b2 (1)
- Bio safety (1)
- Biomarkers (1)
- CD47 (1)
- CMVepidemiology (1)
- COVID 19 (1)
- CPE (1)
- Caco‐2 cells (1)
- Cardiovascular disease risk (1)
- Cardiovascular diseases (1)
- Cell culture (1)
- Cell-to-Cell Spread (1)
- ChAdOx1-S (1)
- Congenital CMVinfection (1)
- Corona virus (1)
- Covid-19 (1)
- Cytomegalovirus (CMV) (1)
- Darunavir (1)
- Detection workflow (1)
- Donor screening (1)
- E protein structure (1)
- EGFR pathway (1)
- ELISA (1)
- ER stress (1)
- Endothelial cells (1)
- Epsilon (1)
- FFP3 respirator (1)
- Filovirus cell entry; attachment factors redundancy; SH-SY5Y cell line; host–pathogen interactions (1)
- Forensic medicine (1)
- HBV (1)
- HCC recurrence (1)
- HCV (1)
- HEV (1)
- HSCT (1)
- Health care workers (1)
- Hepatitis c (1)
- Heterologous prime-boost (1)
- Human immunodeficiency virus (HIV) (1)
- Hypertension (1)
- IAP (1)
- IFA (1)
- IRF-3 (1)
- IgG (1)
- Immunogenicity (1)
- In vitro (1)
- Inactivation (1)
- Inflammation (1)
- Interferon (1)
- Kappa (1)
- Medical history (1)
- Multivariate analysis (1)
- N501Y (1)
- NF-kB (1)
- NGS (1)
- Omicron variant BA.1 (1)
- Otorhinolaryngological (1)
- PAPR (1)
- POCT (1)
- Pandemic (1)
- Pathology (1)
- Personal protective equipment (1)
- Post mortem examination (1)
- Powered air-purifying respirator (1)
- Protein-translocation (1)
- Proteomics (1)
- Quarantine (1)
- RT-PCR-detection (1)
- Reactogenicity (1)
- SARS CoV 2 (1)
- SARS coronavirus (1)
- SARS-CoV-2 testing (1)
- SARS-CoV-2-specific T cells (1)
- SIRPalpha (1)
- SR-BI (1)
- SVR (1)
- Serology (1)
- Seroprevalence (1)
- Stability (1)
- Travel regulations (1)
- Variant of concern (1)
- VeroE6‐eGFP cells (1)
- Viral hepatitis (1)
- Virological testing (1)
- Virus trapping (1)
- Wastewater-based epidemiology (WBE) (1)
- acute liver failure (1)
- animal experiments (1)
- animal models (1)
- antibody tests (1)
- antiviral (1)
- antiviral agents (1)
- antiviral drugs (1)
- antiviral signaling (1)
- aprotinin (1)
- benfooxythiamine (1)
- cathepsin L inhibitor (1)
- cell barrier integrity (1)
- cell culture (1)
- cerebrospinal fluid (1)
- chelator (1)
- coagulation (1)
- coagulopathy (1)
- contact lens solution (1)
- delta (1)
- diagnostic test (1)
- direct-acting antivirals (1)
- drug discovery (1)
- drug repurposing (1)
- drug screening (1)
- elderly (1)
- famotidine (1)
- flavivirus entry factor (1)
- gargle lavage (1)
- genetic diversity (1)
- global diversity (1)
- hepatitis B surface antigen (1)
- hepatitis C virus (1)
- hepatitis D (1)
- hepatitis E (1)
- high throughput (1)
- histamine (1)
- host immune response (1)
- human monoclonal antibody (1)
- human-liver chimeric mouse model (1)
- immunity (1)
- immunosenescence (1)
- immunosuppression (1)
- infection model (1)
- inflammation (1)
- interferon induction (1)
- interferon sensitivity (1)
- intranasal administration (1)
- itraconazole (1)
- live cell imaging (1)
- liver transplantation (1)
- mRNA1273 (1)
- mesenchymal stromal cells (1)
- mice (1)
- molecular surveillance (1)
- monkeypox (1)
- monoclonal antibodies (1)
- monoclonal antibody (1)
- multimorbidity (1)
- nasal swab (1)
- natural selection (1)
- neutralization (1)
- neutralizing antibody (1)
- nucleotide analogue (1)
- orthopoxvirus (1)
- oxLDL (1)
- oxythiamine (1)
- pentose phosphate pathway (1)
- phenotypic screening; (1)
- poxvirus (1)
- prevention (1)
- qRT-PCR detection (1)
- re-emerging virus (1)
- reactivation (1)
- self-collected samples (1)
- semen (1)
- serology (1)
- severe acute respiratory syndrome coronavirus (1)
- severe acute respiratory syndrome coronavirus 2 (1)
- spike mutation (1)
- spike protein (1)
- stem cells (1)
- surrogate ELISA (1)
- tear (1)
- test protocol (1)
- thrombosis (1)
- toll-like receptor (1)
- topical administration (1)
- transduction (1)
- transferrin (1)
- transmission and vector control (1)
- vaccine, (1)
- variant of concern (1)
- variants of concern (1)
- virus (1)
- wastewater-based epidemiology (WBE) (1)
- yellow fever virus (1)
- yellow fever virus tropism (1)
Institute
- Medizin (86) (remove)
Hepatitis B virus (HBV) reactivation in immunosuppressed patients can cause considerable morbidity and mortality. The aim of our study was to evaluate factors associated with acute liver failure (ALF) in HBV reactivation. Clinical, laboratory, and virological data of 87 patients with HBV reactivation were analyzed retrospectively. Teno torque virus (TTV) plasma loads were measured as a measure of immune competence. HBV genomes isolated from 47 patients were analyzed by next-generation sequencing. A functional analysis of identified HBsAg mutants was performed. In patients with ALF the diagnosis was significantly later confirmed than in the non-ALF group. Patients diagnosed during immunosuppression had a milder clinical course compared to later diagnosed patients (p = 0.018, OR = 4.17). TTV viral loads did not differ significantly between the two groups. The HBV genomes isolated from ALF patients had higher viral complexity. A mutation in C-region of HBsAg (L216*), was associated with reduced HBsAg production and secretion. Patients diagnosed with HBV reactivation during immunosuppression had a milder clinical course compared to patients diagnosed during immune reconstitution. ALF was associated with higher viral complexity. An HBsAg mutation (L216*) was found to be more frequent in ALF patients and was associated with reduced HBsAg production and secretion.
Filoviruses infect a wide range of cell types with the exception of lymphocytes. The intracellular proteins cathepsin B and L, two-pore channel 1 and 2, and bona fide receptor Niemann–Pick Disease C1 (NPC1) are essential for the endosomal phase of cell entry. However, earlier steps of filoviral infection remain poorly characterized. Numerous plasma membrane proteins have been implicated in attachment but it is still unclear which ones are sufficient for productive entry. To define a minimal set of host factors required for filoviral glycoprotein-driven cell entry, we screened twelve cell lines and identified the nonlymphocytic cell line SH-SY5Y to be specifically resistant to filovirus infection. Heterokaryons of SH-SY5Y cells fused to susceptible cells were susceptible to filoviruses, indicating that SH-SY5Y cells do not express a restriction factor but lack an enabling factor critical for filovirus entry. However, all tested cell lines expressed functional intracellular factors. Global gene expression profiling of known cell surface entry factors and protein expression levels of analyzed attachment factors did not reveal any correlation between susceptibility and expression of a specific host factor. Using binding assays with recombinant filovirus glycoprotein, we identified cell attachment as the step impaired in filovirus entry in SH-SY5Y cells. Individual overexpression of attachment factors T-cell immunoglobulin and mucin domain 1 (TIM-1), Axl, Mer, or dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) rendered SH-SY5Y cells susceptible to filovirus glycoprotein-driven transduction. Our study reveals that a lack of attachment factors limits filovirus entry and provides direct experimental support for a model of filoviral cell attachment where host factor usage at the cell surface is highly promiscuous.
Environmental stability and infectivity of hepatitis C virus (HCV) in different human body fluids
(2018)
Background: Hepatitis C virus (HCV) is a hepatotropic, blood-borne virus, but in up to one-third of infections of the transmission route remained unidentified. Viral genome copies of HCV have been identified in several body fluids, however, non-parental transmission upon exposure to contaminated body fluids seems to be rare. Several body fluids, e.g., tears and saliva, are renowned for their antimicrobial and antiviral properties, nevertheless, HCV stability has never been systematically analyzed in those fluids.
Methods: We used state of the art infectious HCV cell culture techniques to investigate the stability of HCV in different body fluids to estimate the potential risk of transmission via patient body fluid material. In addition, we mimicked a potential contamination of HCV in tear fluid and analyzed which impact commercially available contact lens solutions might have in such a scenario.
Results: We could demonstrate that HCV remains infectious over several days in body fluids like tears, saliva, semen, and cerebrospinal fluid. Only hydrogen-peroxide contact lens solutions were able to efficiently inactivate HCV in a suspension test.
Conclusion: These results indicate that HCV, once it is present in various body fluids of infected patients, remains infective and could potentially contribute to transmission upon direct contact.
Objective: Chronically HCV-infected orthotopic liver transplantation (OLT) recipients appear to have improved outcomes when their immunosuppressive regimen includes a mammalian target of rapamycin (mTOR) inhibitor. The mechanism underlying this observation is unknown.
Design: We used virological assays to investigate mTOR signalling on the HCV replication cycle. Furthermore, we analysed HCV RNA levels of 42 HCV-positive transplanted patients treated with an mTOR inhibitor as part of their immunosuppressive regimen.
Results: The mTOR inhibitor rapamycin was found to be a potent inhibitor for HCV RNA replication in Huh-7.5 cells as well as primary human hepatocytes. Half-maximal inhibition was observed at 0.01 µg/mL, a concentration that is in the range of serum levels seen in transplant recipients and does not affect cell proliferation. Early replication cycle steps such as cell entry and RNA translation were not affected. Knockdown of raptor, an essential component of mTORC1, but not rictor, an essential component of mTORC2, inhibited viral RNA replication. In addition, overexpression of raptor led to higher viral RNA replication, demonstrating that mTORC1, but not mTORC2, is required for HCV RNA replication. In 42 HCV-infected liver-transplanted or kidney-transplanted patients who were switched to an mTOR inhibitor, we could verify that mTOR inhibition decreased HCV RNA levels in vivo.
Conclusions: Our data identify mTORC1 as a novel HCV replication factor. These findings suggest an underlying mechanism for the observed benefits of mTOR inhibition in HCV-positive OLT recipients and potentiate further investigation of mTOR-containing regimens in HCV-positive recipients of solid organ transplants.
Background & Aims: Hepatitis C virus (HCV) cell entry is mediated by several cell surface receptors, including scavenger receptor class B type I (SR-BI). Oxidized low density lipoprotein (oxLDL) inhibits the interaction between HCV and SR-BI in a noncompetitive manner. We tested whether serum oxLDL levels correlate with sustained virologic response (SVR) rates after interferon-based treatment of chronic hepatitis C.
Methods: Baseline oxLDL was determined in 379 participants with chronic HCV genotype 1 infection from the INDIV-2 study using a commercial enzyme-linked immunosorbent assay. The mechanistic in vitro studies used full-length and subgenomic HCV genomes replicating in hepatoma cells.
Results: In the multivariate analysis, oxLDL was found to be an independent predictor of SVR. Oxidized LDL did not correlate with markers of inflammation (alanine transaminase, ferritin), nor was serum oxLDL affected by exogenous interferon administration. Also, oxLDL did not alter the sensitivity of HCV replication to interferon. However, oxLDL was found to be a potent inhibitor of cell-to-cell spread of HCV between adjacent cells in vitro. It could thus reduce the rate at which new cells are infected by HCV through either the cell-free or cell-to-cell route. Finally, serum oxLDL was significantly associated with the estimated infected cell loss rate under treatment.
Conclusions: Oxidized LDL is a novel predictor of SVR after interferon-based therapy and may explain the previously observed association of LDL with SVR. Rather than being a marker of activated antiviral defenses it may improve chances of SVR by limiting spread of infection to naive cells through the cell-to-cell route.
Background: The sodium-taurocholate cotransporting polypeptide (NTCP) is both a key bile acid (BA) transporter mediating uptake of BA into hepatocytes and an essential receptor for hepatitis B virus (HBV) and hepatitis D virus (HDV). In this study we aimed to characterize to what extent and through what mechanism BA affect HDV cell entry.
Methods: HuH-7 cells stably expressing NTCP (HuH-7/NTCP) and primary human hepatocytes (PHH) were infected with in vitro generated HDV particles. Infectivity in the absence or presence of compounds was assessed using immunofluorescence staining for HDV antigen, standard 50% tissue culture infectious dose (TCID50) assays and quantitative PCR.
Results: Addition of primary conjugated and unconjugated BA resulted in a dose dependent reduction in the number of infected cells while secondary, tertiary and synthetic BA had a lesser effect. This effect was observed both in HuH-7/NTCP and in PHH. Other replication cycle steps such as replication and particle assembly and release were unaffected. Moreover, inhibitory BA competed with a fragment from the large HBV envelope protein for binding to NTCP-expressing cells. Conversely, the sodium/BA-cotransporter function of NTCP seemed not to be required for HDV infection since infection was similar in the presence or absence of a sodium gradient across the plasma membrane. When chenodeoxycolic acid (15 mg per kg body weight) was administered to three chronically HDV infected individuals over a period of up to 16 days there was no change in serum HDV RNA.
Conclusions: Primary BA inhibit NTCP-mediated HDV entry into hepatocytes suggesting that modulation of the BA pool may affect HDV infection of hepatocytes.